Cancer researchers hit a bullseye with new drug target for Ewing sarcoma

Screening a class of recently-developed drug compounds—so-called "CDK inhibitors" capable of blocking CDK7/12/13 proteins—against hundreds of different human cancer cell lines, researchers at Dana-Farber/Boston Children's Cancer and Blood Disorders Center have found that CDK12 inhibitors pack a particularly lethal punch to Ewing sarcoma, a rare cancer typically affecting children and young adults.

Read more: https://medicalxpress.com/news/2018-01-cancer-bullseye-drug-ewing-sarcoma.html